natgillin/translations-raw huggingface dataset:
3 patienter (2 %), der fik docetaxel, ophørte med behandlingen grundet væskeretention, hvorimod 15 patienter (9 %), der fik doxorubicin, stoppede behandlingen grundet hjertetoksicitet (3 tilfælde af letal hjerteinsufficiens). 
Three docetaxel patients (2%) discontinued the treatment due to fluid retention, whereas 15 doxorubicin patients (9%) discontinued due to cardiac toxicity (three cases of fatal congestive heart failure).
Hjertesvigtet kan være moderat til alvorligt og har været associeret med død (se pkt. 
This may be moderate to severe and has been associated with death (see section 4.8).
In vitro-studier har vist, at docetaxels metabolisme kan ændres ved samtidig medicinering med stoffer, som inducerer, hæmmer eller metaboliseres (og således hæmmer enzymet kompetitivt) af cytochrom P450 3A, f.eks ciclosporin, ketoconazol og erythromycin. 
In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds which induce, inhibit or are metabolised by (and thus may inhibit the enzyme competitively) cytochrome P450-3A such as ciclosporine, ketoconazole and erythromycin.
Alle patienter uden forværret sygdom skulle ifølge protokollen modtage CRT (PF/CRT). 
All patients who did not have progressive disease were to receive CRT as per protocol (PF/CRT).
I et farmakokinetisk studie med 7 patienter resulterede samtidig administration af docetaxel og den potente CYP3A4-hæmmer ketoconazol i et signifikant fald i docetaxel-clearance på 49 %. 
In a pharmacokinetic study with 7 patients, the co-administration of docetaxel with the strong CYP3A4 inhibitor ketoconazole leads to a significant decrease in docetaxel clearance by
Docetaxel hver 3. uge 
Docetaxel every 3 weeks
Patienter bør ikke genbehandles med efterfølgende cyklusser af docetaxel indtil neutrofil-antallet gendannes til et niveau > 1.500 celler/mm3 og blodplader gendannes til et niveau > 100.000 celler/mm3. 
Patients should not be retreated with subsequent cycles of docetaxel until neutrophils recover to a level >1,500 cells/mm3 and platelets recover to a level >100,000 cells/mm3.
Docetaxels clearence i kombinationsterapi med cisplatin var sammenlignelig med det observerede ved monoterapi. 
Clearance of docetaxel in combination therapy with cisplatin was similar to that observed following monotherapy.
Alopeci; Neglesygdomme (ikke alvorlig) 
Alopecia; Nail disorders (no severe)
Mere end 1 hætteglas af DOCETAXEL KABI koncentrat til infusionsvæske, opløsning kan blive nødvendigt for at opnå den påkrævede dosis til patienten. 
More than one vial of DOCETAXEL KABI concentrate for solution for infusion may be necessary to obtain the required dose for the patient.
Nervesystemet 
Nervous system
Docetaxels kinetiske profil er dosis-uafhængig og i overensstemmelse med en 3compartment farmakokinetisk model, med halveringstider for α, β og γ faserne på henholdsvis 4 min., 36 min. og 11,1 time. 
The kinetic profile of docetaxel is dose independent and consistent with a three-compartment pharmacokinetic model with half lives for the α, β and γ phases of 4 min, 36 min and 11.1 h, respectively.
• Non-Hodgkin lymfom (en kræftform, som påvirker immunsystemet) og andre kræftformer kan forekomme hos patienter, der behandles med docetaxel sammen med visse andre behandlinger mod kræft. 
• non-Hodgkin lymphoma (a cancer affecting the immune system) and other cancers may occur in patients who are treated with docetaxel together with certain other anticancer treatments.
Overlevelsen var bedre i kombinationsarmen med docetaxel + capecitabin (p = 0,0126). 
Survival was superior in the docetaxel + capecitabine combination arm (p = 0.0126).
I kombination med trastuzumab er den anbefalede dosis af docetaxel 100 mg/m2 hver 3. uge med en ugentlig administration af trastuzumab. 
In combination with trastuzumab the recommended dose of docetaxel is 100 mg/m2 every three weeks, with trastuzumab administered weekly.
I dette studie blev 501 patienter med lokalt fremskredent SCCHN og en WHO funktionsstatus på 0 eller 1, randomiseret i en af to arme. 
In this study, 501 patients, with locally advanced SCCHN, and a WHO performance status of 0 or 1, were randomised to one of two arms.
NAVN OG ADRESSE PÅ INDEHAVEREN AF MARKEDSFØRINGSTILLADELSEN Fresenius Kabi Deutschland GmbH 
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Fresenius Kabi Deutschland GmbH
Post-menopausal * Hazard ratio (TAC/FAC) på mindre end 1 indikerer, at der er en sammenhæng mellem TAC og en længere sygdoms-fri overlevelse, sammenlignet med FAC. 
Post-Menopausal *a hazard ratio (TAC/FAC) of less than 1 indicates that TAC is associated with a longer disease free survival compared to FAC.
Statusskalaen for hoved- og hals underskalaer (PSS-HN) var designet til at måle sprogforståelse, evnen til at indtage føde offentligt samt en normal kost. 
The performance status scale, for head and neck (PSS-HN) subscales designed to measure understandability of speech, ability to eat in public, and normalcy of diet, was significantly in favour of TPF as compared to PF.
Til behandling af patienter med lokalt fremskreden eller metastatisk brystkræft er den anbefalede dosis docetaxel i monoterapi 100 mg/m2. 
For the treatment of patients with locally advanced or metastatic breast cancer, the recommended dose of docetaxel is 100 mg/m2 in monotherapy.
Efter endt kemoterapi, med et minimum interval på 4 uger og et maksimum interval på 7 uger, blev de patienter, hvis sygdom ikke forværredes, strålebehandlet (RT) i 7 uger i henhold til de fastlagte retningslinier (PF/RT). 
At the end of chemotherapy, with a minimal interval of 4 weeks and a maximal interval of 7 weeks, patients whose disease did not progress received radiotherapy (RT) according to institutional guidelines for 7 weeks (PF/RT).
Efter administration af docetaxel 100 mg/m2 givet som infusion over 1 time, fandtes den gennemsnitlige maksimale plasmakoncentration at være 3,7 mg/ml med et AUC på 4,6 h.μg/ml. 
Following the administration of a 100 mg/m2 dose given as a one-hour infusion a mean peak plasma level of 3.7 μg/ml was obtained with a corresponding AUC of 4.6 h.μg/ml.
Patienter med operabel, lymfeknude-negativ brystkræft, egnet til behandling med kemoterapi (GEICAM 9805) 
Patients with operable node-negative breast cancer eligible to receive chemotherapy (GEICAM 9805)
Effektresultaterne er vist i tabellen nedenfor: 
Efficacy results are presented in the table below:
Forhøjet lakrimation 
Lacrimation increased
Akut respiratorisk distress syndrom og tilfælde af interstitiel pneumoni/pneumonitis, interstitiel lungesygdom, lungefibrose og respirationssvigt, sommetider letale, er rapporteret sjældent. 
Acute respiratory distress syndrome and cases of interstitial pneumonia/ pneumonitis, interstitial lung disease, pulmonary fibrosis and respiratory failure sometimes fatal have rarely been reported.
Tidligere behandling skal have omfattet et anthracyklin 
Previous therapy should have included an anthracycline.
• 1.276 patienter (744 i TAX 316 og 532 i GEICAM 9805), som fik docetaxel i kombination med doxorubicin og cyclophosphamid (klinisk vigtige behandlingsrelaterede bivirkninger er nævnt). 
• 1,276 patients (744 and 532 in TAX 316 and GEICAM 9805 respectively) who received docetaxel in combination with doxorubicin and cyclophosphamide (clinically important treatment related adverse events are presented).
Hvis samtidig anvendelse af en potent CYP3A4-hæmmer (f.eks. ketoconazol, itraconazol, clarithromycin, indinavir, nefazodon, nelfinavir, ritonavir, saquinavir, telithromycin og voriconazol) ikke kan undgås, er tæt klinisk overvågning nødvendig, og justering af docetaxeldosis kan være hensigtsmæssig under behandling med potente CYP3A4-hæmmere (se pkt. 
If the concomitant use of a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) cannot be avoided, a close clinical surveillance is warranted and a dose-adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor (see section 4.4).
Kontakt straks lægen, hospitalsfarmaceuten eller sundhedspersonalet, hvis du oplever mavesmerter eller -ømhed, diaré, endetarmsblødning, blodig afførring eller feber. 
Tell your doctor, hospital pharmacist, or nurse immediately if you have abdominal pain or tenderness, diarrhoea, rectal haemorrhage, blood in stool or fever.
Hos patienter i behandling med TAC-regimet for lymfeknude-positiv brystkræft har risikoen for CHF vist sig at være højere i det første år efter behandling (se pkt. 
In patients treated with the TAC regimen for node positive breast cancer, the risk of CHF has been shown to be higher during the first year after treatment (see sections 4.8 and 5.1).
Medicinen hedder DOCETAXEL KABI. 
The name of this medicine is DOCETAXEL KABI.
Begyndelsen af moderat og alvorlig retention var forsinket hos patienter (median kumulativ dosis: 818,9 mg/m2) med præmedicinering set i forhold til patienter uden præmedicinering (median kumulativ dosis: 489,7 mg/m2). 
The onset of moderate and severe retention is delayed (median cumulative dose: 818.9 mg/m2) in patients with premedication compared with patients without premedication (median cumulative dose: 489.7 mg/m2); however, it has been reported in some patients during the early courses of therapy.
DOCETAXEL KABI må IKKE anvendes, hvis du er gravid eller planlægger at blive gravid, medmindre din læge udtrykkelig ønsker det. 
DOCETAXEL KABI must NOT be administered if you are pregnant unless clearly indicated by your doctor.
• Docetaxel 30 mg/m2 administreret ugentlig i de første 5 uger i en 6 ugers behandlingsrunde i 5 behandlingsrunder. 
• Docetaxel 30 mg/m2 administered weekly for the first 5 weeks in a 6 week cycle for 5 cycles.
Cisplatins farmakokinetiske profil, når det administreres kort efter infusion med docetaxel, er sammenlignelig med profilen for cisplatin, når det administreres alene. 
The pharmacokinetic profile of cisplatin administered shortly after docetaxel infusion is similar to that observed with cisplatin alone.
De mest almindelige bivirkninger af DOCETAXEL KABI givet alene er: Fald i antallet af røde og hvide blodlegemer , hårtab, kvalme, opkastning, sår i munden, diarré og træthed. 
The most commonly reported adverse reactions of DOCETAXEL KABI alone are: decrease in the number of red blood cells or white blood cells, alopecia, nausea, vomiting, sores in the mouth, diarrhoea and tiredness.
Disse cyklusser blev gentaget hver 3. uge i 3 cyklusser. 
The cycles were repeated every 3 weeks for 3 cycles.
• Følelsesløshed eller stikkende og prikkende fornemmelse eller smerte i led eller muskler 
• feeling of numbness or pins and needles or pain in the joints or muscles
I kombination med capecitabin 
In combination with capecitabine
Docetaxel indgives som en 1-times infusion hver 3. uge. 
Docetaxel is administered as a one-hour infusion every three weeks.
Efter den sidste cyklus af kemoterapi, fik patienter i begge arme, der havde positive østrogen- og/eller progesteronreceptorer tamoxifen 20 mg daglig i op til 5 år. 
In both arms, after the last cycle of chemotherapy, patients with positive oestrogen and/or progesterone receptors received tamoxifen 20 mg daily for up to 5 years.
Din læge bør straks igangsætte behandling. 
Your doctor should address them immediately.
Hjertesvigt er observeret hos patienter, som fik docetaxel i kombination med trastuzumab, specielt efter kemoterapi med anthracyclin (doxorubicin eller epirubicin). 
Heart failure has been observed in patients receiving docetaxel in combination with trastuzumab, particularly following anthracycline (doxorubicin or epirubicin)-containing chemotherapy.
Der findes ingen data på administration af docetaxel til gravide. 
There is no information on the use of docetaxel in pregnant women.
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE Yderkarton 
PARTICULARS TO APPEAR ON OUTER PACKAGING OUTER CARTON
Da fordelene hos patienter med 4+ lymfeknuder ikke var statistisk signifikante for sygdoms-fri overlevelse (DFS) og total overlevelse (OS), blev det positive fordel/risiko forhold for TAC-patienter med 4+ lymfeknuder ikke fuldt demonstreret i den endelige analyse (se pkt. 
As the benefit observed in patient with 4+ nodes was not statistically significant on disease-free survival (DFS) and overall survival (OS), the positive benefit/risk ratio for TAC in patients with 4+ nodes was not fully demonstrated at the final analysis (see section 5.1).
Der var mindre brug af smertestillende morfika (p < 0,01), smertestillende ikke-morfika (p < 0,01), anden ikke-sygdomsrelateret medicin (p = 0,06) og strålebehandling (p < 0,01) hos de patienter, der fik behandling med docetaxel ved doseringen 75 mg/m2 end hos patienterne, der fik bedste palliative behandling. 
There was less use of morphinic analgesic (p < 0.01), non-morphinic analgesics (p < 0.01), other disease-related medicinal products (p = 0.06) and radiotherapy (p < 0.01) in patients treated with docetaxel at 75 mg/m² compared to those with BSC.
Alvorligheden af bivirkningerne ved DOCETAXEL KABI kan forøges, når DOCETAXEL KABI gives i kombination med andre kemoterapeutiske lægemidler. 
The severity of adverse events of DOCETAXEL KABI may be increased when DOCETAXEL KABI is given in combination with other chemotherapeutic agents.
docetaxel + trastuzumab var effektivt til patienterne, uanset om de havde fået adjuverende anthracyclin eller ikke. 
Docetaxel plus trastuzumab was efficacious in patients whether or not they had received prior adjuvant anthracyclines.
Hvis DOCETAXEL KABI koncentrat eller infusionsvæske skulle komme på huden, så vask omgående og grundigt med sæbe og vand. 
If DOCETAXEL KABI concentrate or infusion solution should come into contact with skin, wash immediately and thoroughly with soap and water.
Flere grad 3/4 bivirkninger blev observeret for DOCETAXEL KABI monoterapi (55,4 %) sammenlignet med paclitaxel (23,0 %). 
More grade 3/4 adverse events were observed for docetaxel monotherapy (55.4%) compared to paclitaxel (23.0%).
Primær G-CSF-profylakse bør overvejes til patienter, som får docetaxel-, doxorubicin- og cyclophosphamid- (TAC)-adjuverende behandling for brystkræft. 
Primary G-CSF prophylaxis should be considered in patients who receive docetaxel, doxorubicin and cyclophosphamide (TAC) adjuvant therapy for breast cancer.
I studiet TAX 316 oplevede 26 patienter (3,5%) i TAC-armen og 17 patienter (2,3%) i FACarmen kongestivt hjertesvigt. 
In study TAX316, 26 patients (3.5%) in the TAC arm and 17 patients (2.3%) in the FAC arm experienced congestive heart failure.
Docetaxel øgede responsraten (33 % mod 12 %, p < 0,0001), forlængede tiden til progression (19 uger mod 11 uger, p = 0,0004), samt forlængede overlevelsen (11 måneder mod 9 måneder, p = 0,01). 
Docetaxel increased response rate (33% vs. 12%, p < 0.0001), prolonged time to progression (19 weeks vs. 11 weeks, p= 0.0004) and prolonged overall survival (11 months vs. 9 months, p= 0.01).
Den 1-årige overlevelsesrate var signifikant længere med docetaxel (40 %) end for bedste palliative behandling (16 %). 
The 1-year survival rate was also significantly longer in docetaxel (40%) versus BSC (16%).
Vær særlig opmærksom på at informere din læge, hvis du får diarré, sår i munden, følelsesløshed, stikkende og prikkende fornemmelser eller feber, og giv lægen resultatet af dine blodprøver. 
In particular, please inform your doctor in case of diarrhoea, sores in the mouth, feeling of numbness or pins and needles, fever and give her/him results of your blood tests.
Der er rapporteret om alvorlige symptomer såsom udslæt efterfulgt af afskalning, som har ført til afbrydelse eller ophør med docetaxel-behandlingen (se pkt. 
Severe symptoms such as eruptions followed by desquamation which lead to interruption or discontinuation of docetaxel treatment were reported (see section 4.2).
I tidligere kemoterapi skal anthracyclin eller et alkylerende stof have været anvendt. 
Previous chemotherapy should have included an anthracycline or an alkylating agent.
DOCETAXEL KABI i kombination med doxorubicin og cyclophosphamid er indiceret til adjuverende behandling af patienter med: 
DOCETAXEL KABI in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:
Fra et mikrobiologisk synspunkt skal rekonstituering/fortynding ske under kontrollerede og aseptiske forhold, og lægemidlet skal anvendes straks. 
From a microbiological point of view, reconstitution/dilution must take place in controlled and aseptic conditions and the medicinal product should be used immediately.
Patienter med 4+lymfeknuder 
Patients with 4+ nodes
Begge regimer blev indgivet på dag 1 hver 3. uge. 
Both regimens were administered on day 1 every 3 weeks.
Adjuverende behandling til brystkræft 
Adjuvant therapy for breast cancer
På grund af risiko for skadelige påvirkninger af barnet skal amning derfor ophøre under behandling med docetaxel. 
Consequently, because of the potential for adverse reactions in nursing infants, breast feeding must be discontinued for the duration of docetaxel therapy.
Tabellen nedenfor viser, at hyppigheden af grad 4 neutropeni, febril neutropeni og neutropenisk infektion var lavere hos patienter, der fik G-CSF profylaktisk, efter det blev gjort obligatorisk i TAC- armen i GEICAM-studiet. 
Table below shows that the incidence of Grade 4 neutropenia, febrile neutropenia and neutropenic infection was decreased in patients who received primary G-CSF prophylaxis after it was made mandatory in the TAC arm - GEICAM study.
Akut respiratorisk distress syndrom, interstitiel pneumoni/pneumonitis, interstitiel lungesygdom, lungefibrose og respirationssvigt er blevet rapporteret og kan være associeret med dødelig udgang. 
Acute respiratory distress syndrome, interstitial pneumonia/pneumonitis, interstitial lung disease, pulmonary fibrosis and respiratory failure have been reported and may be associated with fatal outcome.
De hyppigst rapporterede symptomer var rødme, udslæt med eller uden kløe, trykken for brystet, rygsmerter, dyspnø og feber eller kulderystelser. 
The most frequently reported symptoms were flushing, rash with or without pruritus, chest tightness, back pain, dyspnoea and fever or chills.
EVENTUELLE ANDRE SÆRLIGE ADVARSLER Cytotoksisk 
OTHER SPECIAL WARNING(S), IF NECESSARY Cytotoxic
Udtrak aseptisk den ønskede mængde af DOCETAXEL KABI koncentrat til infusionsvæske, opløsning ved brug af kalibreret sprøjte. 
Aseptically withdraw the required amount of DOCETAXEL KABI concentrate for solution for infusion using a calibrated syringe.
I denne undersøgelse blev 358 patienter med inoperabelt, lokalt fremskreden SCCHN og WHO funktionsstatus 0 eller 1, randomiseret i en af to behandlingsarme. 
In this study, 358 patients with inoperable locally advanced SCCHN, and WHO performance status 0 or 1, were randomised to one of two treatment arms.
Uden at påvirke overlevelsestiden (docetaxel 15 måneder mod doxorubicin 14 måneder, p = 0,38) eller tiden til progression (docetaxel 27 uger mod doxorubicin 23 uger, p = 0,54), øgede docetaxel responsraten (52 % mod 37 %, p = 0,01) og gav hurtigere respons (12 uger mod 23 uger, p = 0,007). 
Without affecting overall survival time (docetaxel 15 months vs. doxorubicin 14 months, p = 0.38) or time to progression (docetaxel 27 weeks vs. doxorubicin 23 weeks, p = 0.54), docetaxel increased response rate (52% vs. 37%, p = 0.01) and shortened time to response (12 weeks vs. 23 weeks, p= 0.007).
For behandling efter forudgående svigt af platinbaseret kemoterapi, er den anbefalede dosis 75 mg/m2 givet som enkeltstof. 
For treatment after failure of prior platinum-based chemotherapy, the recommended dose is 75 mg/m² as a single agent.
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket. 
If you get any side effects, talk to your doctor, hospital pharmacist or nurse.
Med en hazard ratio < 1 kan docetaxel + cisplatin+5-FU anvendes med fordel *Cox model (tilpasning til primær tumor, T og N kliniske stadier og PSWHO) **Logrank test *** Chi-square-test 
A hazard ratio of less than 1 favours docetaxel + cisplatin + 5-FU *Cox model (adjustment for Primary tumour site, T and N clinical stages and PSWHO) **Logrank test *** Chi-square test
Kliniske fordelsparametre 
Clinical benefit parameters
Docetaxel plus trastuzumab1 
Docetaxel plus trastuzumab1 n = 92
Anden primær malignitet er blevet rapporteret, når docetaxel blev givet i kombination med anticancer behandlinger, der vides at være forbundet med anden primær malignitet. 
Second primary malignancies have been reported when docetaxel was given in combination with anticancer treatments known to be associated with second primary malignancies.
Patienter med svær væskeretention i form af pleuraekssudat og perikardieekssudat samt ascites, skal observeres nøje. 
Patients with severe fluid retention such as pleural effusion, pericardial effusion and ascites should be monitored closely.
I tilfælde af efterfølgende episoder med kompliceret neutropeni, bør dosis af docetaxel reduceres fra 60 mg/m2 til 45 mg/m2. 
If subsequent episodes of complicated neutropenia occur the docetaxel dose should be reduced from 60 to 45 mg/m2.
Gennemsnitsværdierne for den totale clearence og steady-state distributionsvolumen var henholdsvis 21 l/h/m2 og 113 l. Den interindividuelle variation i totalclearance var ca 50 %. 
Mean values for total body clearance and steady-state volume of distribution were 21 l/h/m2 and 113 l, respectively.
Blandt de patienter, der fik docetaxel hver tredje uge, var hyppigheden af relaterede negleforandringer ≥ 10 % højere i patientgruppen på 65 år og derover, end i gruppen af yngre patienter. 
In patients treated with docetaxel every three weeks, the incidence of related nail changes occurred at a rate ≥ 10% higher in patients who were 65 years of age or greater compared to younger patients.
Hvert hætteglas er til engangsbrug og skal anvendes straks. 
Each vial is for single use and should be used immediately.
Til patienter, som i SCCHN pivotalstudiet udviklede kompliceret neutropeni (inklusive prolongeret neutropeni, febril neutropeni eller infektion), blev G-CSF anbefalet som profylakse (f.eks. dag 6-15) i alle efterfølgende cyklusser. 
In the pivotal SCCHN studies patients who experienced complicated neutropenia (including prolonged neutropenia, febrile neutropenia, or infection), it was recommended to use G-CSF to provide prophylactic coverage (eg, day 6-15) in all subsequent cycles.
• Mitoxantrone 12 mg/m2 hver 3. uge i 10 behandlingsrunder. 
• Mitoxantrone 12 mg/m2 every 3 weeks for 10 cycles.
Denne indlægsseddel blev senest ændret 
This leaflet was last revised in {MM/YYYY}
I kombination med capecitabin er de mest almindelige behandlingsrelaterede bivirkninger (≥ 5 %) medtaget, som blev rapporteret i et fase III-studie med brystkræftpatienter, hvor anthracyclinbehandling ikke havde haft effekt (se: produktresuméet for capecitabin). 
For combination with capecitabine, the most frequent treatment-related undesirable effects (≥ 5%) reported in a phase III study in breast cancer patients failing anthracycline treatment are presented (see capecitabine summary of product characteristics).
Som førstebehandling indgives 75 mg/m2 doxetaxel i kombinationsbehandling med doxorubicin (50 mg/m2). 
In first-line treatment, docetaxel 75 mg/m2 is given in combination therapy with doxorubicin (50 mg/m2).
Tid indtil progressiv sygdom var længere i kombinationsarmen med Xeloda + docetaxel (p < 0,0001). 
Time to progressive disease was superior in the docetaxel + capecitabine combination arm (p < 0.0001).
6.1 Hjælpestoffer Polysorbat 80 
Polysorbate 80
Samtidig anvendelse af docetaxel og potente CYP3A4-hæmmere (f.eks. ketoconazol, itraconazol, clarithromycin, indinavir, nefazodon, nelfinavir, ritonavir, saquinavir, telithromycin og voriconazol) bør undgås (se pkt. 
The concomitant use of docetaxel with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) should be avoided (see section 4.5).